[1] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin, 2007, 7(57): 43–46.
[2] 叶定伟, 朱耀. 中国前列腺癌的发病趋势. 中国临床肿瘤学教育专辑, 2007, 616–620.
[3] Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol, 2000, 16(1): 653–699.
[4] Zhou JG, Zhau HE, Lin BY, Nelson PS, Visakorpi T, Saramaki O, Chung LWK. DNA microarray identified a novel PC-1gene differentially expressed by human pros-tate tissues and tumor cell lines. The Fifth Asian Congress on Urology, Beijing, 2000.
[5] Wang RX, Xu JC, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, John P, Nelson PS, Marshall FF, Zhau HE, Chung LWK. PrLZ, a novel prostate-specific and androgen-re- sponsive gene of the TPD52 family, amplified in chromo some 8q21.1 and overexpressed in human prostate cancer. Cancer Res, 2004, 64(5): 1589–1594.
[6] Zhang H, Wang J, Pang B, Liang RX, Li S, Huang P, Wang R, Chung LWK, Zhau HE, Huang C, Zhou JG. PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res, 2007, 67(18): 8906–8913.
[7] Huang MJ, Cheng Y, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol, 2006, 34(11): 1480–1489.
[8] Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am, 1999, 26(2): 263–273.
[9] Shachaf CM, Kopelman AM, Arvanitis C, Karlsson Å, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop M, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentia-tion and tumour dormancy in hepatocellular cancer. Nature, 2004, 431(7012): 1112–1117.
[10] Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Ge-netic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol, 1998, 153(1): 141–148.
[11] Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest, 2003, 112(11): 1724–1731.
[12] 杜彦艳, 刘鑫, 单保恩. Wnt/β-catenin信号转导通路与肿瘤关系的研究进展. 肿瘤, 2009, 29(8): 803–806.
[13] Liang S, Rizzo1 CA, Spires TE, Platero IS, Wu Q, Lin T, Gottardis MM, Attar RM. The androgen receptor can sig-nal through Wnt/β-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol, 2008, 9: 4.
[14] Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res, 2009, 19(6): 683–697. |